|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TACC1 |
Gene summary for TACC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TACC1 | Gene ID | 6867 |
| Gene name | transforming acidic coiled-coil containing protein 1 | |
| Gene Alias | Ga55 | |
| Cytomap | 8p11.22 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | O75410 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6867 | TACC1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.86e-09 | -4.05e-01 | 0.0155 |
| 6867 | TACC1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.74e-03 | 5.51e-01 | -0.1088 |
| 6867 | TACC1 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.65e-04 | 5.06e-01 | -0.1954 |
| 6867 | TACC1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.74e-06 | -3.65e-01 | 0.0674 |
| 6867 | TACC1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.80e-10 | 7.00e-01 | 0.294 |
| 6867 | TACC1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.36e-19 | 1.19e+00 | 0.281 |
| 6867 | TACC1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.21e-06 | -6.65e-01 | 0.2585 |
| 6867 | TACC1 | F007 | Human | Colorectum | FAP | 9.75e-04 | -3.67e-01 | 0.1176 |
| 6867 | TACC1 | A002-C-010 | Human | Colorectum | FAP | 5.28e-03 | -3.14e-01 | 0.242 |
| 6867 | TACC1 | A001-C-207 | Human | Colorectum | FAP | 1.44e-02 | -1.97e-01 | 0.1278 |
| 6867 | TACC1 | A015-C-203 | Human | Colorectum | FAP | 4.44e-25 | -3.47e-01 | -0.1294 |
| 6867 | TACC1 | A015-C-204 | Human | Colorectum | FAP | 3.65e-04 | -1.75e-01 | -0.0228 |
| 6867 | TACC1 | A014-C-040 | Human | Colorectum | FAP | 4.24e-03 | -6.82e-02 | -0.1184 |
| 6867 | TACC1 | A002-C-201 | Human | Colorectum | FAP | 2.83e-17 | -4.02e-01 | 0.0324 |
| 6867 | TACC1 | A001-C-119 | Human | Colorectum | FAP | 7.63e-06 | -3.12e-01 | -0.1557 |
| 6867 | TACC1 | A001-C-108 | Human | Colorectum | FAP | 3.85e-13 | -6.89e-02 | -0.0272 |
| 6867 | TACC1 | A002-C-205 | Human | Colorectum | FAP | 1.74e-22 | -3.90e-01 | -0.1236 |
| 6867 | TACC1 | A015-C-005 | Human | Colorectum | FAP | 5.62e-04 | -2.56e-01 | -0.0336 |
| 6867 | TACC1 | A015-C-006 | Human | Colorectum | FAP | 1.01e-14 | -3.13e-01 | -0.0994 |
| 6867 | TACC1 | A015-C-106 | Human | Colorectum | FAP | 4.09e-06 | 1.19e-02 | -0.0511 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:19028502 | Liver | Cirrhotic | microtubule cytoskeleton organization involved in mitosis | 52/4634 | 147/18723 | 2.52e-03 | 1.51e-02 | 52 |
| GO:00070514 | Liver | Cirrhotic | spindle organization | 62/4634 | 184/18723 | 3.88e-03 | 2.10e-02 | 62 |
| GO:000705111 | Liver | HCC | spindle organization | 116/7958 | 184/18723 | 1.40e-08 | 3.40e-07 | 116 |
| GO:000705211 | Liver | HCC | mitotic spindle organization | 80/7958 | 120/18723 | 7.43e-08 | 1.50e-06 | 80 |
| GO:190285011 | Liver | HCC | microtubule cytoskeleton organization involved in mitosis | 93/7958 | 147/18723 | 2.91e-07 | 5.09e-06 | 93 |
| GO:00219872 | Lung | IAC | cerebral cortex development | 27/2061 | 114/18723 | 8.78e-05 | 1.77e-03 | 27 |
| GO:00215432 | Lung | IAC | pallium development | 33/2061 | 169/18723 | 7.51e-04 | 9.82e-03 | 33 |
| GO:00309002 | Lung | IAC | forebrain development | 61/2061 | 379/18723 | 1.52e-03 | 1.61e-02 | 61 |
| GO:19028503 | Lung | IAC | microtubule cytoskeleton organization involved in mitosis | 27/2061 | 147/18723 | 5.23e-03 | 3.97e-02 | 27 |
| GO:003090011 | Lung | AIS | forebrain development | 55/1849 | 379/18723 | 2.37e-03 | 2.48e-02 | 55 |
| GO:00070515 | Lung | MIAC | spindle organization | 22/967 | 184/18723 | 2.14e-04 | 7.50e-03 | 22 |
| GO:00070523 | Lung | MIAC | mitotic spindle organization | 15/967 | 120/18723 | 1.32e-03 | 2.44e-02 | 15 |
| GO:190285012 | Lung | MIAC | microtubule cytoskeleton organization involved in mitosis | 17/967 | 147/18723 | 1.55e-03 | 2.65e-02 | 17 |
| GO:00070526 | Oral cavity | OSCC | mitotic spindle organization | 85/7305 | 120/18723 | 1.44e-12 | 6.23e-11 | 85 |
| GO:19028506 | Oral cavity | OSCC | microtubule cytoskeleton organization involved in mitosis | 99/7305 | 147/18723 | 2.94e-12 | 1.18e-10 | 99 |
| GO:00070517 | Oral cavity | OSCC | spindle organization | 117/7305 | 184/18723 | 1.16e-11 | 4.17e-10 | 117 |
| GO:00219876 | Oral cavity | OSCC | cerebral cortex development | 57/7305 | 114/18723 | 1.09e-02 | 3.71e-02 | 57 |
| GO:00215435 | Oral cavity | OSCC | pallium development | 81/7305 | 169/18723 | 1.11e-02 | 3.76e-02 | 81 |
| GO:190285014 | Oral cavity | LP | microtubule cytoskeleton organization involved in mitosis | 63/4623 | 147/18723 | 9.97e-07 | 2.50e-05 | 63 |
| GO:000705213 | Oral cavity | LP | mitotic spindle organization | 53/4623 | 120/18723 | 2.36e-06 | 5.22e-05 | 53 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TACC1 | SNV | Missense_Mutation | c.886G>T | p.Gly296Cys | p.G296C | O75410 | protein_coding | tolerated(0.06) | possibly_damaging(0.59) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| TACC1 | SNV | Missense_Mutation | rs779300910 | c.488N>T | p.Ser163Leu | p.S163L | O75410 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TACC1 | SNV | Missense_Mutation | rs758999833 | c.1640N>T | p.Ala547Val | p.A547V | O75410 | protein_coding | tolerated(0.22) | benign(0.091) | TCGA-AN-A0XP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TACC1 | SNV | Missense_Mutation | c.1084N>A | p.Ala362Thr | p.A362T | O75410 | protein_coding | tolerated(0.28) | benign(0.015) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TACC1 | SNV | Missense_Mutation | rs778594616 | c.1895N>A | p.Arg632Gln | p.R632Q | O75410 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| TACC1 | insertion | In_Frame_Ins | novel | c.1619_1620insATATCTGTATGGAGT | p.Pro540_Val541insTyrLeuTyrGlyVal | p.P540_V541insYLYGV | O75410 | protein_coding | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| TACC1 | SNV | Missense_Mutation | novel | c.1340N>G | p.His447Arg | p.H447R | O75410 | protein_coding | tolerated(0.38) | benign(0.055) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TACC1 | SNV | Missense_Mutation | rs377342873 | c.938N>T | p.Ser313Leu | p.S313L | O75410 | protein_coding | tolerated(0.09) | benign(0.037) | TCGA-EA-A5ZD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TACC1 | SNV | Missense_Mutation | c.1484N>C | p.Asp495Ala | p.D495A | O75410 | protein_coding | tolerated(0.07) | benign(0.043) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TACC1 | SNV | Missense_Mutation | c.824C>G | p.Thr275Arg | p.T275R | O75410 | protein_coding | tolerated(0.4) | benign(0.133) | TCGA-Q1-A6DW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |